Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA May Reconsider RMAT Requests If Resubmitted With Sufficient Clinical Data

Executive Summary

Rejection of an RMAT request does not mean necessarily mean the FDA won't grant one. The agency will accept new clinical data to support the application through a “reconsideration” process, industry official says.

You may also be interested in...



Regenerative Medicine Therapies: Manufacturing Changes May Not Impact RMAT Designation

Final guidance notes that preliminary clinical evidence may come from studies conducted outside the US, says historical controls may be considered in clinical trial designs.

FDA Accentuates Venclexta Superiority To Imbruvica

FDA denied breakthrough therapy request until AbbVie and Roche demonstrated substantial improvement over available treatment in 17p deletion chronic lymphocytic leukemia, review documents show.

INTERVIEW: Cook MyoSite Eyes Japan As Cell Therapy Trials Progress

In the wake of supportive regulations introduced in 2014, more and more firms in the regenerative medicines space are eyeing Japan as an attractive market. US-based Cook MyoSite is no exception.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS142531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel